Posters
- Resources
- Posters
Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.
NEW! CYTO 2024 Posters
NEW! AACR 2024 Posters
Clinical Flow Cytometry
Hematological Malignancies
Humanized Models
Lumin Acuity
Solid Tumor PDX Models
Raptamer-Drug Conjugates as Molecularly Targets Cancer Therapeutics - AACR 2023
Combining Multiomics and Histological Assessment to Identify Patient-derived Xenograft Models of Invasive Lobular Carcinoma - San Antonio Breast Cancer Symposium 2022
TumorGraft3D & Co-Culture Platforms
A Novel TumorGraft3D immune co-culture platform for high throughput immune-oncology screening - SITC 2023
Identification of synergistic combination of molecular targeted agents and chemotherapy using TumorGraft3D and Lumin platform - Tumor Models Boston 2023
Unique 3D Organoids Autologous TIL Co-Culture Platform Enables High Throughput Immune-Oncology Drug Response Studies - AACR 2021
Development of a 3D Organoid Autologous TIL Co-Culture Platform for High Throughput Immuno-Oncology Studies - SITC 2020